7,7-Difluorooctanal

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7,7-Difluorooctanal
• 英文别名: 7,7-difluorooctanal
• 化学式: C₈H₁₄F₂O
• 分子量: 164.19
• InChiKey: CWPRFSRRWGKBED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• SPIROIMIDAZOLONE DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2433940B9

  公开（公告）日：2015-10-28
• GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE
  申请人：Genzyme Corporation

  公开号：EP2320886B1

  公开（公告）日：2017-06-28
• 2-acylaminopropanol-type glucosylceramide synthase inhibitors
  申请人：Genzyme Corporation

  公开号：EP2594563B1

  公开（公告）日：2018-07-18
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20180093981A1

  公开（公告）日：2018-04-05

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
• US9744153B2
  申请人：——

  公开号：US9744153B2

  公开（公告）日：2017-08-29